Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 243 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Chalazion
Interventions
SUN-131 1.5% TDS, Placebo TDS
Drug
Lead sponsor
Senju USA, Inc.
Industry
Eligibility
6 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
65
States / cities
Chandler, Arizona • Prescott, Arizona • Sun City, Arizona + 56 more
Conditions
Long QT Syndrome
Interventions
Testosterone, Progesterone, Placebo, Ibutilide
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Chemo Brain, Chemotherapy-related Cognitive Impairment, Chemo Fog, Breast Cancer, Chemobrain
Interventions
Transdermal nicotine, Placebo Transdermal Patch
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
35 Years to 80 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Urge Urinary Incontinence, Urinary Frequency
Interventions
Oxybutynin, Placebo
Drug
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
55
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Laguna Hills, California + 50 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Flushing Reduction Associated With Nitrates

NCT02714205
Conditions
Menopausal Hot Flashes
Interventions
transdermal nitroglycerin, Placebo
Drug
Lead sponsor
Alison Huang, MD
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Oakland, California • San Francisco, California
Conditions
Primary Ovarian Insufficiency, Female Infertility Due to Diminished Ovarian Reserve
Interventions
Testosterone cream (0.5mg per gram), DHEA, Placebo
Drug · Dietary Supplement
Lead sponsor
Center for Human Reproduction
Other
Eligibility
38 Years to 44 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
2
States / cities
New York, New York • Rochester, New York
Conditions
Depressive Disorder
Interventions
Transdermal Nicotine Patch, Transdermal Placebo Patch
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
20 Years to 70 Years · Female only
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Kansas City, Missouri
Completed Phase 2 Interventional Results available

Estrogen Receptor Beta and Mood

NCT03689543
Conditions
Perimenopause-Related Depression
Interventions
Estradiol, ER Beta Agonist, Placebo, Provera
Drug · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
45 Years to 65 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Accepts healthy volunteers Results available

Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study

NCT00736255
Conditions
Attention Deficit Hyperactivity Disorder, Nicotine Dependence
Interventions
Transdermal Nicotine Patch, Lis-dexamphetamine (Vyvanse), Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

NCT03838484
Conditions
Schizophrenia, Impulsive Behavior
Interventions
Nicotine Patch, 7 Mg/24 Hr, Placebo patch
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
d-Amphetamine Transdermal Patch, Placebo patch
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Irvine, California • Miami, Florida • Las Vegas, Nevada
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Estrogen Variability and Irritability During the Menopause Transition

NCT05388656
Conditions
Menopause, Irritable Mood
Interventions
Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo, Progesterone 200 mg
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 59 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 75 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
42
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Conditions
Postoperative Pain
Interventions
transdermal nicotine patch
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Restless Legs Syndrome, End-Stage Renal Disease
Interventions
Rotigotine, Placebo
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Brandon, Florida • Newton, Massachusetts • West Seneca, New York + 3 more
Conditions
Depressive Disorder, Major
Interventions
Testosterone gel, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
30 Years to 65 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Healthy
Interventions
Estradiol Transdermal System Placebo - Alternate Adhesive, Estradiol Transdermal System Placebo - Current Adhesive
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
40 Years to 66 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Advanced Idiopathic Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Gilbert, Arizona • Sunnyvale, California • Tampa, Florida + 7 more
Conditions
Chronic Low Back Pain
Interventions
Bupivacaine TTS (Bupivacaine Patch), Placebo patch
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years to 70 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
21
States / cities
Tempe, Arizona • La Mesa, California • Torrance, California + 18 more
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue

NCT00490555
Conditions
Healthy
Interventions
Testosterone gel, Dutasteride, Depo-Medroxyprogesterone (DMPA), Placebo Testosterone gel, Placebo dutasteride, Placebo DMPA
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Schizophrenia
Interventions
Low Dose Asenapine maleate transdermal patch, High Dose Asenapine maleate transdermal patch, Placebo
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Jersey City, New Jersey
Conditions
Skin Irritation, Sensitization
Interventions
Donepezil TDS, Vehicle TDS
Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
40 Years and older
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Lincoln, Nebraska
Conditions
Idiopathic Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Oxnard, California • Ormond Beach, Florida + 21 more